Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hereditary Angioedema (HAE) Therapeutics Market

Hereditary Angioedema (HAE) Therapeutics Market Trends

Report ID: GMI11102
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Hereditary Angioedema Therapeutics Market Trends

The ongoing innovation in the development of targeted therapies, such as new complement inhibitors and bradykinin B2 receptor antagonists, is driving market growth. These therapies offer better efficacy and safety compared to traditional treatments, making them attractive to both patients and healthcare providers. For instance, in May 2024, Ionis Pharmaceuticals, Inc. announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE), demonstrating a significant and sustained reduction in mean monthly HAE attack rates, with continued attack rate improvement of over 90% after one year of treatment for both monthly and every two-month dosing. Thus, the development and approval of new drugs are expanding the therapeutic options available for HAE, which is expected to contribute to market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global hereditary angioedema therapeutics industry was valued at USD 4.1 billion in 2023 and is anticipated to register 9.2% CAGR between 2024 and 2032 due to the rising awareness of hereditary angioedema and advancements in diagnostic technology.

The hospital pharmacies segment in the market is predicted to record 9.5% CAGR through 2032 due to their expertise in managing HAE therapies and providing essential diagnostic tools for ensuring proper treatment and accurate diagnoses.

Asia Pacific hereditary angioedema therapeutics market held 46.8% revenue share in 2023 due to its strong research and development infrastructure and expanded access to specialized care.

Attune Pharmaceuticals, BioCryst Pharmaceuticals, Inc., Biomarin, CSL Behring LLC, Intellia Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc., Pharming Healthcare, Inc., and Pharvaris, among others.